Meeting
2011 ASCO Annual Meeting
Comparison of 12 current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials.
Authors
X. Li
Department of Medical Oncology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
X. Li , Q. Lin , M. Dong , X. Wu , L. Wei , J. Wen , X. Ma , Z. Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Clinical Trial Design
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2567)
Abstract #
2567
Poster Bd #
4F
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
First Author: Mathias Earl Palmer
Poster
2022 ASCO Annual Meeting
Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274).
First Author: Linda R. Mileshkin
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib combined with TACE among patients with intermediate and advanced-stage hepatocellular carcinoma (HCC).
First Author: Lin Zheng
Poster
2015 Gastrointestinal Cancers Symposium
Comparative efficacy of sorafenib dose in patients with advanced hepatocellular carcinoma (HCC) with varying liver dysfunction.
First Author: Sukeshi R. Patel